Accelerated aging associated with cancer characteristics and treatments among breast cancer survivors

• DOI: 10.18632/aging.206218
• Publication Date: 2025-03-07T20:18:37Z
• Authors: Cong Wang; Jill B. De Vis; Kirsten Nguyen; Brigitte Jia; Mason Alford; Marjan Rafat; Bapsi Chakravarthy; Xiao-Ou Shu

Breast cancer (BC) survivors may experience accelerated aging due to detrimental effects of BC and/or its treatments. Our study aims evaluate Phenotypic Age Acceleration (PAA), a biological age measure, among patients and assess associations with characteristics In this including 1264 (age 54.7±11.7) 429 cancer-free controls 49.9±12.4), we evaluated the differences in PAA (ΔPAA) by treatments at multiple time points using linear mixed models. Overall, had higher than diagnosis (ΔPAA=3.73, <i>p</i><0.001), 1-year (ΔPAA=1.68, <i>p</i>=0.001), 10-year (ΔPAA=1.16, <i>p</i>=0.03) post-diagnosis. At post-diagnosis, stage III/IV (vs 0), intermediate- high- low-) grade were associated 4.48 (<i>p</i><0.001), 1.26 (<i>p</i>=0.03), 1.95 (<i>p</i>=0.001), respectively; triple-negative hormone receptor+/HER2-) was lower (ΔPAA=-1.96, <i>p</i>=0.004). Compared receiving surgery or without radiotherapy, observed post-diagnosis those additional chemotherapy (ΔPAA=4.26, <i>p</i><0.001) for endocrine therapy (ΔPAA=2.89, <i>p</i>=0.001). conclusion, up 10 years especially high/intermediate-grade BC, systemic treatment.